Tokyo, Feb. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060509) titled 'Role of background metformin therapy in cardiorenal outcomes in type 2 diabetic patients treated with SGLT2 inhibitors' on Feb. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Tokyo Bay Urayasu Ichikawa Medical Center
Condition:
Condition - Type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify whether background antidiabetic therapy, especially Metformin, modifies the cardiovascular and renal protective effects of SGLT2 inhibitors
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - The patients with T2DM (age >=18 y/o) who visited our outpatient clinic between April 2014 and September 2018 and were newly given SGLT2 inhibitors
Key exclusion criteria - Patients on steroid therapy or immunosuppressive agents and those with multiple missing data
Target Size - 220
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2025 Year 04 Month 01 Day
Date of IRB - 2026 Year 01 Month 23 Day
Anticipated trial start date - 2025 Year 04 Month 01 Day
Last follow-up date - 2026 Year 03 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069222
Disclaimer: Curated by HT Syndication.
